|
Indications and Dosage
Intravenous
Refractory acute lymphoblastic leukaemia Child: As a single agent: 30 mg/m2 every 5 days to 180 mg/m2 wkly given over 30-60 min infusion. With other agents: 165 mg/m2 twice wkly for 8-9 doses with cytarabine or up to 250 mg/m2 wkly for 4-8 wk with vincristine and prednisone. Given as an infusion over 30-60 min.
|
|
Renal Impairment
Dose adjustment may be needed.
|
|
Hepatic Impairment
Dose adjustment may be needed.
|
|
Contraindications
Hypersensitivity to polyoxyethylated castor oil. Pregnancy and lactation. Severe hepatic and renal failure.
|
|
Special Precautions
Monitor CBC, electrolytes, renal and hepatic function at baseline and before each treatment. Avoid extravasation. Reduce dose in Down's syndrome, hepatic and renal impairment.
|
|
Adverse Reactions
Reversible alopoecia, nausea, vomiting, diarrhoea, mucositis, rash, fever, neurotoxicity, hepatic or renal dysfunction, infection, bleeding, secondary acute myeloid leukaemia. Hypotension upon rapid IV.
Potentially Fatal: Severe hypersensitivity reactions. |
|
IV/Parenteral: D
|
|
Drug Interactions
Decreased teniposide concentration by phenytoin, phenobarbital, carbamazepine; increased teniposide toxicity with ciclosporin; increased risk of myelosuppression with colony stimulating factors, zidovudine. Interferes with GI absorption of other oral drugs eg. digoxin. Reduced response to vaccines.
|
|
Action
Description: Teniposide has antineoplastic properties similar to etoposide. It appears to produce its cytotoxic effects by damaging DNA, thereby preventing or altering DNA synthesis. Given alone or with other antineoplastic agents in treatment of refractory acute lymphoblastic leukaemia.
|
|
Storage
Store 2-8°C.
|
|
MIMS Class
|
Sign Out
